ADMA Biologics ADMA APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's apic, share-based payment arrangement, option, increase for cost recognition.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's APIC, share-based payment arrangement, option, increase for cost recognition?
- ADMA Biologics (ADMA) reported APIC, share-based payment arrangement, option, increase for cost recognition of $6.33M in Q1 2026.
- How has ADMA Biologics's APIC, share-based payment arrangement, option, increase for cost recognition changed year-over-year?
- ADMA Biologics's APIC, share-based payment arrangement, option, increase for cost recognition increased by 36.9% year-over-year, from $4.62M to $6.33M.
- What is the long-term trend for ADMA Biologics's APIC, share-based payment arrangement, option, increase for cost recognition?
- Over 2 years (2023 to 2025), ADMA Biologics's APIC, share-based payment arrangement, option, increase for cost recognition has grown at a 79.9% compound annual growth rate (CAGR), from $6.19M to $20.03M.
- What does APIC, share-based payment arrangement, option, increase for cost recognition mean?
- This reflects the non-cash accounting adjustments made to equity resulting from share-based compensation plans. It captures the expense recognized for stock options or equity grants provided to employees over the requisite service period.